

RESEARCH ARTICLE

Open Access

Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring

Enrique Alcalde-Cabero¹, Javier Almazán-Isla¹, Antonio García-Merino², Joao de Sá³ and Jesús de Pedro-Cuesta^{1*}

Abstract

Background: A debate surrounding multiple sclerosis epidemiology has centred on time-related incidence increases and the need of monitoring. The purpose of this study is to reassess multiple sclerosis incidence in the European Economic Area.

Methods: We conducted a systematic review of literature from 1965 onwards and integrated elements of original research, including requested or completed data by surveys authors and specific analyses.

Results: The review of 5323 documents yielded ten studies for age- and sex-specific analyses, and 21 studies for time-trend analysis of single data sets. After 1985, the incidence of multiple sclerosis ranged from 1.12 to 6.96 per 100,000 population, was higher in females, tripled with latitude, and doubled with study midpoint year. The north registered increasing trends from the 1960s and 1970s, with a historic drop in the Faroe Islands, and fairly stable data in the period 1980-2000; incidence rose in Italian and French populations in the period 1970-2000, in Evros (Greece) in the 1980s, and in the French West Indies in around 2000.

Conclusions: We conclude that the increase in multiple sclerosis incidence is only apparent, and that it is not specific to women. Monitoring of multiple sclerosis incidence might be appropriate for the European Economic Area.

Keywords: Incidence, Monitoring, Multiple sclerosis, Time-trends, Surveillance

Background

Multiple sclerosis (MS) is a chronic, demyelinating disease with frequent worsening episodes denoted as bouts or MS exacerbations, which are characteristic of the so-called relapsing-remitting form (RRMS) and absent in the less common, primary progressive form (PPMS). Despite intensive research over decades and early identification of susceptibility genes [1], its aetiology remains poorly known, with more than 50 susceptibility alleles identified and a considerable proportion of these regulated by Vitamin D [2,3]. Environmental factors, probably acting before adulthood, also appear to be implicated, as reflected by birth-cohort and season-of-birth effects

[4,5], selected results of twin studies [6] and changing incidence among populations migrating to environments with different risk [7].

The most lively debate surrounding MS epidemiology at the beginning of the millennium [8-10] could perhaps be said to have centred on time-related increases in MS incidence (MSI), whether genuine or ascertainment-related. Subsequently and due, moreover, to potential post-vaccination incidents or side-effects of immunomodulating therapies, interest in MSI monitoring or surveillance gained wider recognition [11-15]. Several MS registers/studies have developed tools for, e.g., correcting the effects of diagnostic delays or using capture-recapture methods, appropriate for improving the quality and comparability of MSI measurements [16-18]. Design of incidence thresholds and other alarm signals may be problematic, since there is considerable uncertainty worldwide about expected MSI in specific

* Correspondence: jpedro@isciii.es

¹National Centre for Epidemiology, Carlos III Institute of Health, and Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Av Monforte de Lemos 5, Madrid 28029, Spain
Full list of author information is available at the end of the article

populations for a number of reasons, such as rising trends, seasonality of bouts and validity of diagnostic criteria. The goals and formal components of public health-sponsored surveillance of MS have not yet been defined.

The purpose of this paper was twofold: firstly, it was an attempt to describe and compare MSI reported in recent decades among populations served by medical systems providing regular access to qualified neurological expertise, magnetic resonance imaging (MRI) and new treatments, potentially covered by publicly-run or -funded national health services, such as those of the European Economic Area (EEA) Member States. The non-EU members of EEA (Iceland, Liechtenstein and Norway) have agreed to enact legislation similar to that passed in the EU in the areas of social policy, consumer protection, environment and statistics. Secondly, the paper aimed to explore and describe the historical presence in the above-mentioned survey populations of three, specific, potentially interrelated MS-incidence features: 1) pseudo-periodic or occasional changes in incidence [19-21]; 2) changes in magnitude or shape of the age-specific incidence curve, occasionally reported as bimodal [20,22] and attributed to an increase in incidence among women aged over 40 years [10,23,24]; and, 3) a set of interrelated changes, perceived as a function of calendar time and interpreted as components of potential alarm signals (rising incidence of RRMS; increasing female/male incidence rate ratio and shortened diagnostic delay from clinical onset) [19,25-28].

Methods

Principles for the undertaking of systematic reviews were followed [29].

Study identification

We searched for reports in MEDLINE using "Multiple Sclerosis" and "Incidence", both as MeSH terms and as TEXT WORDS issued between 1 January 1965 and 31 May 2012. The search yielded 5317 unrepeated documents. Analysis of document titles by two authors, EAC and JPC, searching for issues linked to MSI measurements, enabled identification by mutual agreement for the purposes of perusing the abstract (where available) of 344 of the above-mentioned 5317 documents plus a further six obtained from one of the author's files. The same two authors then examined the abstracts, identified surveys reporting incidence periods from 1985 onwards, and mutually agreed on 122 of the above-mentioned 350 documents for full-text review. At a later step, the following two criteria sets were used for selection of papers for analysis of age- and sex-specific MSI from 1985 onwards, and time-related changes in MSI in EEA populations including those predating 1985.

Survey selection for studying age- and sex-specific MSI

The quality criteria used for results analyses were: (1) use of diagnostic criteria explicitly designed for MS/MS forms; (2) study incidence period either wholly post-1985 or, alternatively, at least two thirds post-1985 in cases where 1985 was included; (3) provision of age- and sex-specific measurements. Where different periods were covered by different reports for the same geographically-defined population, the most informative (usually the most recent) was selected. Exclusion criteria were as follows: (1) lack of reference to MS forms included in counts; (2) arbitrarily chosen accrual of ≤ 30 cases; and, (3) reports in languages other than Danish, English, French, Norwegian, Spanish or Swedish.

Survey selection for reviewing time-trends or time-related changes

The quality criteria applied were different and less strict than those used for age- and sex-specific incidence, and required that: 1) measurements included either crude or age- and sex-adjusted incidence rates for an observation period of, at least, an arbitrary 10-year duration in cases where 1985 was included; 2) explicit MS diagnostic criteria were used; 3) figures were based on clinical onset rather than MS diagnostic periods.

Data-extraction or -completion

Study of age- and sex-specific MSI

A full-text review by both authors of a number of selected articles on age- and sex-specific MSI measurements in geographically-defined EEA populations suggested that there were insufficient or inadequate reported age-group data to be combined using models, due to one or more of the following factors: being represented only in graphs [30-32]; being incomplete for population groups, i.e., having numerators with zero cases generally in the youngest or oldest age-groups [8,33-37]; containing gross errors in rate calculations, i.e., for incidence in both sexes [38]; pertaining to age-groups that were too wide, selected (in general truncated) or mismatched [39-42]; or corresponding to protracted incidence periods, i.e., 1965-1993, 1968-1997 or 1975-1994, which probably encompassed multiple changes in MS diagnostic policies/traditions that were potentially heterogeneous by age at onset [43-45]. To complete the data, authors of reported surveys were thus contacted in specific instances by JPC via e-mail, correspondence address or telephone number of their institutional affiliations (usually hospital departments). Thus, for reports not yet definitely excluded on the basis of criteria defined in subsection 1.a. above, the authors of 13 surveys [30-35,37-42,46] were requested to furnish such data in a different format, e.g., age at clinical onset instead of age at MS diagnosis, or distribution by age of incident MS case different to that shown. Subsequently,

new case-related data were obtained from five surveys [30-32,37,40] or completed with data extracted from graphs, specifically from four of them deemed useful for combination [31,32,37,40]. For 12 surveys, the population structure in new age-groups or complementary demographic data were obtained from the authors or official statistics bodies [8,30-37,40,46,47]. Eight of the 12 surveys for which new data were requested/obtained [8,31,32,34-37,40] fulfilled criteria for inclusion of study results. Since the data from Modena were included in two different reports [36,47], we studied a total of ten age- and sex-specific incidence sets drawn from nine different populations [8,10,31,32,34-37,40,48]. Only two of the eleven surveys finally selected for study provided reported data initially deemed valid for analysis purposes [10,48] (see Figure 1 for a summary description of attrition flow). Reported or obtained numerators and denominators used for analyses are presented in the Table 1.

Review of time trends or time-related changes

No data were requested from authors for this purpose. Review results for specific MSI, generally at 5- or, alternatively, at >5- [8,10,19,21,27,28,34,36,41,47,49-56] or 1-year calendar time intervals [31,57,58] were obtained from original reports, disregarding other study-interval durations. Updated data were used for Ferrara [34,43] and Catania [10,32].

Incidence measurements and comparisons

Rates and specific indicators

For each specific survey, age- and sex-adjusted incidences were computed using the European standard population. Female/male (F/M) ratios were obtained, firstly from the number of cases and secondly from stratified analysis (Mantel-Haenszel estimator i.e., F/M M-H). Where not reported, diagnostic delay was calculated from differences between mean or median ages at onset and diagnosis for either incidence or diagnostic periods, if mentioned.

Comparative measurements

Incidence rate ratios were obtained from log-linear models using the binomial distribution. Five analyses were performed using Poisson models. The core analysis was conducted by fitting a global model, in which the independent variables were age-sex, midpoint of study period and categorised diagnostic criteria. F/M ratios were computed from models. Time and latitude trends were described from linear change. Secondary analyses were conducted separately for populations of: both sexes aged below 35 years at onset; both sexes aged ≥35 years at onset; and women or men aged ≥35 years at onset. Calculations were made using the Stata 11 software package. Diagnostic criteria were categorised into the following three variable values: Poser clinically definite and probable; Poser and McDonald or other MRI dependent criteria; and other criteria (McAlpine, Schumacher, and mixed non-MRI related). Midpoint of




Figure 1 Attrition flow towards study selection.

Table 1 Reported and rearranged data from MS incidence surveys presented in Figure 3

Study		Men			Women			Both		
First author Reference	Age group	Cases	Person-years	Rate	Cases	Person-years	Rate	Cases	Person-years	Rate
Debouverie 2007 [31]	0-14	0	3,070,347	0.00	7	2,911,480	0.24	7	5,981,827	0.12
	15-24	59	2,191,949	2.69	213	2,072,309	10.28	272	4,264,258	6.38
	25-34	154	2,236,211	6.89	445	2,199,900	20.23	599	4,436,111	13.50
	35-44	151	2,262,937	6.67	339	2,249,492	15.07	490	4,512,429	10.86
	45-54	93	1,827,995	5.09	137	1,782,369	7.69	230	3,610,364	6.37
	55-64	21	1,458,543	1.44	32	1,542,168	2.08	53	3,000,711	1.77
	65+	2	1,680,520	0.12	5	2,584,219	0.19	7	4,264,739	0.16
Guidetti 1995 [36]	0-14	0	449,088	0.00	0	428,838	0.00	0	877,926	0.00
	15-24	12	437,867	2.74	20	424,286	4.71	32	862,153	3.71
	25-34	7	429,913	1.63	25	425,059	5.88	32	854,972	3.74
	35-44	9	420,283	2.14	16	419,570	3.81	25	839,853	2.98
	45-54	1	407,265	0.25	11	409,216	2.69	12	816,481	1.47
	55-64	0	384,447	0.00	2	416,345	0.48	2	800,792	0.25
	65+	0	414,027	0.00	0	595,139	0.00	0	1,009,166	0.00
Alonso 2007 [48]	0-14	0	1,114,646	0.00	0	1,061,240	0.00	0	2,175,886	0.00
	15-24	6	711,643	0.84	24	700,702	3.43	30	1,412,345	2.12
	25-34	50	928,136	5.39	115	926,436	12.41	165	1,854,572	8.90
	35-44	57	860,894	6.62	155	837,502	18.51	212	1,698,396	12.48
	45-54	51	800,963	6.37	111	780,853	14.22	162	1,581,816	10.24
	55-64	29	592,600	4.89	31	596,522	5.20	60	1,189,122	5.05
	65+	5	754,786	0.66	8	1,078,718	0.74	13	1,833,504	0.71
Nicoletti 2005 [32]	0-14	2	297,120	0.67	1	281,850	0.35	3	578,970	0.52
	15-24	10	251,490	3.98	19	246,740	7.70	29	498,230	5.82
	25-34	22	237,360	9.27	34	240,670	14.13	56	478,030	11.71
	35-44	12	205,920	5.83	25	226,150	11.05	37	432,070	8.56
	45-54	7	177,620	3.94	17	203,130	8.37	24	380,750	6.30
	55-64	3	158,980	1.89	3	193,760	1.55	6	352,740	1.70
	65+	0	205,740	0.00	0	295,230	0.00	0	500,970	0.00

Table 1 Reported and rearranged data from MS incidence surveys presented in Figure 3 (Continued)

Joensen 2010 [40]	0-14	0	125,615	0.00	0	118,653	0.00	0	244,268	0.00
	15-24	3	81,263	3.69	6	69,516	8.63	9	150,779	5.97
	25-34	5	74,267	6.73	9	63,934	14.08	14	138,201	10.13
	35-44	6	75,305	7.97	5	66,389	7.53	11	141,694	7.76
	45-54	3	64,103	4.68	5	55,218	9.06	8	119,321	6.70
	55-64	0	49,604	0.00	1	44,487	2.25	1	94,091	1.06
	65+	0	59,298	0.00	1	71,896	1.39	1	131,194	0.76
Sundstrom 2003 [37]	0-14	1	255,257	0.40	1	244,079	0.40	2	499,336	0.40
	15-24	5	175,802	2.90	14	169,431	8.40	19	345,233	5.60
	25-34	18	179,111	10.00	32	166,142	19.20	50	345,253	14.40
	35-44	16	182,644	8.70	23	171,520	13.40	39	354,164	10.90
	45-54	7	163,908	4.20	12	157,093	7.50	19	321,001	5.90
	55-64	0	126,402	0.00	4	131,128	3.10	4	257,530	1.60
	65+	0	189,679	0.00	0	239,325	0.00	0	429,004	0.00
Granieri 2007 [34]	0-14	0	247,388	0.00	2	232,900	0.86	2	480,288	0.42
	15-24	10	282,723	3.54	17	267,370	6.36	27	550,093	4.91
	25-34	21	370,041	5.68	55	353,479	15.56	76	723,520	10.50
	35-44	13	348,169	3.73	41	349,768	11.72	54	697,937	7.74
	45-54	8	336,728	2.38	18	350,939	5.13	26	687,667	3.78
	55-64	1	331,387	0.30	4	366,978	1.09	5	698,365	0.72
	65+	0	443,139	0.00	2	656,512	0.30	2	1,099,651	0.18
Granieri 2008 [35]	0-14	0	31,856	0.00	0	28,859	0.00	0	60,708	0.00
	15-24	2	25,489	7.85	4	24,735	16.17	6	50,196	11.95
	25-34	3	35,513	8.45	11	40,625	27.08	14	76,022	18.42
	35-44	0	32,290	0.00	5	33,221	15.05	5	65,509	7.63
	45-54	2	27,336	7.32	2	27,582	7.25	4	54,887	7.29
	55-64	1	22,396	4.47	2	22,356	8.95	3	44,736	6.71
	65+	0	27,157	0.00	1	36,490	2.74	1	63,483	1.58

Table 1 Reported and rearranged data from MS incidence surveys presented in Figure 3 (Continued)

Nicoletti 2010 [10]	0-14	0	129,630	0.00	0	122,860	0.00	0	252,490	0.00
	15-24	3	103,300	2.90	13	101,785	12.77	16	205,085	7.80
	25-34	10	115,110	8.69	27	114,755	23.53	37	229,865	16.10
	35-44	11	104,500	10.53	20	114,380	17.49	31	219,880	14.10
	45-54	11	98,320	11.19	8	105,025	7.62	19	198,345	9.58
	55-64	4	76,320	5.24	1	91,740	1.09	5	168,060	2.98
	65+	0	111,475	0.00	0	167,980	0.00	0	275,855	0.00
Cabre 2009 [8]	0-14	1	1,388,049	0.07	2	1,351,144	0.15	3	2,739,193	0.11
	15-24	6	848,215	0.71	17	837,479	2.03	23	1,685,694	1.36
	25-34	8	808,481	0.99	35	926,145	3.78	43	1,734,626	2.48
	35-44	7	814,933	0.86	30	931,847	3.22	37	1,746,780	2.12
	45-54	2	608,781	0.33	18	699,425	2.57	20	1,308,206	1.53
	55-64	1	447,677	0.22	2	511,278	0.39	3	958,955	0.31
	65+	0	530,373	0.00	1	731,100	0.14	1	1,261,473	0.08

study period for incidence, latitude in degrees, and F/M M-H obtained from prior analysis were used as continuous variables.

Time-trends

Two independent approaches to time-trends were adopted. Firstly, time-trends from 1985 onwards were studied using mid time points for survey data from models based on ten data sets. Secondly, the reported time series from incidence surveys providing either crude, or age- or age- and sex-adjusted figures for periods encompassing 1985 or after in the EEA were identified for 19 EEA populations in 21 reports. Trends were visually examined from crude or adjusted rates plotted in graphs. When providing the data requested, survey authors occasionally gave their views on the impact had by changes in patient-management traditions on changes in incidence: these views will be referred to below as personal communications.

Results

The above-mentioned 122 documents selected for full-text perusal generated the 37 articles listed in Table 2 and initially considered for potential data requests. Their epidemiological features prior to data completion are shown here mainly for the purposes of assessing possible selection bias and impact of omissions. In general, reported incidences referred to all MS forms, with two surveys providing separate, crude or age- and sex-specific RRMS and PPMS data [54,59]. Surveys reporting incidence for intervals prior to 1985 covered long study periods dating back several decades, e.g., up to 1943 for the Faroes [19,21] and 1955 for Nuoro, Italy [27]. We also included a survey conducted in San Marino, a mini-state not formally belonging to the EEA, with human development indicators similar to or higher than those of EEA countries and specialised medical services shared with Italy [35]. Of the 37 reports, four were used for comparing age-specific incidence only [35,37,40,48], 16 provided data for studying trends [19,21,27,28,41,43,49-58] and seven could be used for both purposes [8,10,31,32,34,36,47]. Ten studies were excluded [24,26,30,33,38,39,42,46,59,60], four due to incidences calculated from data sets based on age at diagnosis, i.e., explicitly reporting MS diagnoses instead of clinical onsets [30,33,46,60]. The geographical distribution of studies selected for each purpose is depicted in Figure 2. Given the political concept of the EEA, surveys included ethnically, racially and geographically heterogeneous populations.

Crude and age- and sex- adjusted incidence figures using the European standard population, data on diagnostic delay, latitude and mid time point, F/M M-H, and details of diagnostic criteria for the ten best-quality surveys are listed in Table 3. Effects of adjustment on

incidence figures were modest, with crude figures for both sexes ranging from 1.14 to 7.93 per 100,000 person years, and age- and sex-adjusted figures ranging from 1.12 to 7.25 per 100,000 person years, with the extreme levels for the French West Indies and San Marino displaying an almost similar 6- to 7-fold variation. The highest incidence was reported for San Marino (1990-2005), with Poser definite and probable MS diagnostic criteria, and the lowest for the French West Indies (1992-2007), with McDonald criteria. F/M ratios calculated from case numbers ranged from 1.59 to 4.20, and those for F/M M-H had a similar range, 1.68 to 3.79, with figures being lower in the Faroes (1986-2007) and Catania (1990-1999) and higher in the French West Indies. The lowest incidence and highest F/M ratios were seen for the French West Indies. Latitudes varied continentally from 37.3 to 65.0 degrees north, with a 15.2 degree outlier in the French West Indies. The length of diagnostic delay from onset was reported in four surveys, all Italian, ranging from a mean of 21 months in Catania during the period 1990-1999, to a mean of 6.1 months in Ferrara in 2003 and one month (number of patients not specified) in San Marino in 2005. The more recent the study period, the shorter the diagnostic delay. Poser diagnostic criteria were used in six surveys [10,31,32,34,35,37], McDonald or Poser/McDonald criteria combined in three [8,40,48], and McAlpine's criteria in the first survey [36]. An aspect that remained unclear was the likelihood of laboratory-supported forms being included in Poser's forms, denoted by authors as "definite and probable" [8,31,34,35,48], with the proportion of the laboratory-supported probable cases, where specified, being 11% [37]. The F/M ratio did not change with study midpoint using linear regression but showed a modest, albeit statistically significant, decrease when the French West Indies survey was excluded, -2.6% (-4.7%- -0.6%) annually. The F/M ratio decreased significantly with latitude, -2.9% (-3.5%- -2.2%) per degree, and modestly -0.6% (-1.4%- 0.2%) when French West Indian data were excluded (Table 3). Data were deemed too sparse for testing linear associations between incidences and length of diagnostic delays reported in Table 3 (data not shown), or between incidences and F/M figures.

Age- and sex-specific incidences for ten surveys are depicted in Figure 3. In general, incidence among women was nil at ages under 15 (five surveys) and ≥ 65 years, and low at ages 55-64 years, peaked at 25-34 years in general and at 35-44 years solely in the UK study, frequently reaching values of 20-30 per 100,000. The lowest figures were seen: for the survey conducted in Reggio Emilia-Modena in 1985-1990, using Poser criteria; and in particular, for the recent study conducted in the French West Indies in 1992-2007 using McDonald's revised criteria. Among men, age-specific incidence was less stable and lower, suggesting a trend to peak

Table 2 Epidemiological features of selected studies

	Study population	Study period	Study	Sex- and age-specific counts	Diagnostic criteria	Other relevant information	Data obtained from author or external sources (yes/no)	F/M ratio (incident cases)	Criteria fulfilled for inclusion in incidence, by age and sex, trend, both or none
	First author and reference	Number of years and intervals	Number of cases (period)			Diagnostic delay (DD) in years			
						Mean age at onset/diagnosis			
1	Faroe Islands Denmark Joensen 2011 [19]	1943-2007 65 7	81	NO	<1986 Poser CD,CPr >1986 Poser, McDonald and Thompson	Mean age at onset 32y	NO	1.25	Trend
2	South-west Sardinia Italy Cocco 2011 [33]	1958-2007 50 5		YES	McDonald	-	NO		None
3	Iceland Eliasdottir 2011 [46]	2002-2007 6 1	136	YES	Poser CD for PPMS	Mean age at diagnosis 36.3y Mean age at onset 32y	YES	3	None
4	Oppland Norway Risberg 2011 [55]	1989-2001 13 3	148	NO	Poser D and Pr, otherwise NS	-	NO	2.02	Trend
5	Faroe Islands Denmark Joensen 2010 [40]	1986-2007 22 1	43	YES	Poser and/or McDonald, for PPMS	36y at onset	NO	1.53	Age- and sex-specific incidence
6	Ostrobothnia Finland Krokki 2010 [24]	1992-2007 16 1	374	NO	Poser CD McDonald CD	Mean age at onset 31.7y Mean age at diagnosis 35.9y	NO		None
7	Catania Italy Nicoletti 2011 [10]	1975-2004 30 6	367 (75-04) 108 (00-04)	YES	Poser CD,Cpr,LSPr	Mean DD 1.4y Age at onset increasing with time	NO	1.55	Both
8	Cardiff (Wales) United Kingdom Hirst 2009 [38]	1985-2007 23 1	582	NO	Poser and McDonald (otherwise NS)	-	NO	2.83	None
9	West Indies France Cabre 2009 [8]	1992-2007 15 3	130	YES	Revised McDonald	Mean age at onset 34.2y	YES	4.2	Both

Table 2 Epidemiological features of selected studies (Continued)


10	San Marino Italy Granieri 2008 [35]	1990-2005 16 1	33	YES	Poser D,Pr	Mean DD decreasing with time (1.5 to 0.08y)	YES	3.12	Age- and sex-specific incidence
11	Greece 3 regions Papathanasopoulos 2008 [60]	1984-2006 23 4	834	NO	Poser and McDonald D (otherwise NS)	Mean DD 2.62y decreasing with time (3.23 to 1.79y) Mean age at onset 31.41y	NO	1.38	None
12	Ferrara Italy Granieri 2007 [34]	1965-2003 39 4	200 (90-03) 421 (65-03)	YES	Poser CD,CP	Mean DD decreasing with time (1.25 to 0.5y)	YES	2.21	Both
13	UK cohort Alonso 2007 [48]	1993-2000 8 1	642	YES	Poser D,Pr, McDonald D,Pr	-	NO	2.24	Age- and sex-specific incidence
14	Lorraine France Debouverie 2007 [31]	1990-2002 13 1	1658	YES	Poser D,Pr	-	YES	2.45	Both
15	Hordaland Norway Grytten 2006 [51]	1953-2002 50 10	878	NO	Poser	Mean DD decreasing with time (9.8-0.9y)	NO	1.9	Trend
16	Nordland Norway Alstadhaug 2005 [30]	1970-1999 30 6	259 (70-99) 183 (85-99)	YES	Poser CDPr,,LSDPr	Mean DD 4.7y Mean age at diagnosis 39y	YES	1.87	None
17	Catania Italy Nicoletti 2005 [32]	1975-1999 25 5	155 (90-99)	YES	Poser CDPr,LSDPr	Mean at onset 33.3y Mean DD 1.7y	YES	1.77	Both
18	Sassari Italy Pugliatti 2005 [54]	1965-1999 34 7	689	NO	Poser	DD range 13.0-0.9y decreasing with time Age at onset increasing with time	NO	2.57	Trend
19	Monreale City Italy Ragonese 2004 [41]	1981-2000 20 2	19	YES	Poser D,Pr	Mean DD 9.2y	NO	-	Trend
20	Evros	1974-1999	56	NO	Poser CD,LSD	-	NO	2.8	Trend

Table 2 Epidemiological features of selected studies (Continued)

	Greece	26							
	Piperidou 2003 [53]	5							
21	Vasterbotten County	1988-1997	133	YES	Poser	-	NO	1.83	Age- and sex-specific incidence
	Sweden	10							
	Sundström 2003 [37]	1							
22	Finland 3 districts	1979-1993	1066	NO	Poser CD or Lublin et al for PPMS	Mean age at diagnosis for districts (35.7,39.3,39.7y)	NO	1.6	None
	Sumelahti 2003 [59]	15							
		2							
23	Lower (<i>Bajo</i>) Aragon	1985-2002	42	NO	Poser CD,CPr	DD 2y	NO	1.93	Trend
	Spain	18				Mean age at onset 29y			
	Modrego 2003 [58]	1							
24	Padova	1980-2000	580	NO	Poser	Decreasing DD with time	NO	1.92	Trend
	Italy	20				34y			
	Ranzato 2003 [28]	4							
25	Iceland	1951-1999	372	NO	Poser	-	NO	1.9	Trend
	Benedikz 2002 [49]	49							
		10							
26	Faroe Islands	1943-1994	54	NO	Poser CD,CPr	Individual age at onset available	NO	-	Trend
	Denmark	52							
	Kurtzke 2001 [21]	8							
27	Enna, Sicily	1986-1995	16	YES	Poser	Mean DD 3y	NO	1.28	None
	Italy	10							
	Grimaldi 2001 [39]	1							
28	Oslo	1972-1996	794	NO	Poser CD	For persons diagnosed 1986-1999	NO	2.38	None
	Norway	25				DD 5.2y			
	Celius 2001 [26]	5				Age at diagnosis 38.1y			
29	Nuoro	1955-1995	469	YES	Poser (unspecified), Allison & Millar and Schumacher	Mean DD 4.61y	NO	1.95	Trend
	Italy	41				Mean age at onset 28.5y			
	Granieri 2000 [27]	8							
30	Alcoi	1986-1997	45	NO	Poser CD,CPr	-	NO	4	Trend
	Spain	12				Mean age at onset 35.1y			
	Mallada 2000 [57]	1							

Table 2 Epidemiological features of selected studies (Continued)

31	Troms & Finnmark Norway Gronlie 2000 [50]	1974-1992 19 4	139	NO	Rose DPRPs & Poser CD,CPr,LSD	Mean DD 4.5y Mean age at onset/diagnosis available	NO	1.36	Trend
32	Bagueria city Italy Salemi 2000 [42]	1985-1994 10 1	20	YES	Poser	Age at diagnosis 34.6y Mean DD 2.6y	NO	1.86	None
33	North-western Sardinia Italy Rosati 1996 [56]	1962-1991 30 6	277	YES	Poser CD,CPr,LSD,LSPr	DD range 8.0-1.8y decreasing with time Mean age at onset 27y	NO	2.46	Trend
34	Ferrara Italy Granieri 1996 [43]	1965-1993 29 6	252	YES	Poser CD,CPr	DD range 6.1-1.9y decreasing with time Mean age at onset for specific forms	NO	2.07	Trend
35	More & Romsdal Norway Midgard 1996 [52]	1950-1991 42 8	330	NO	McAlpine	DD potentially available 6y 39.2y	NO	1.41	Trend
36	Reggio Emilia & Modena Italy Guidetti 1995 [36]	1970-1990 6 4	316 (70-90) 105 (85-90)	YES	McAlpine CD,CPr	- Mean age at onset 30.75y	YES	2.01	Both
37	Modena Italy Cavalletti 1994 [47]	1970-1990 6 4	183 (70-90) 59 (85-90)	YES	McAlpine D,Pr	- Mean age at onset 30.8y	YES	1.9	Both



at later ages in some recent surveys in the UK and Catania [10,48].

Results from log-linear models are described in Table 4. We used ten data sets from surveys undertaken in different, independent populations, fulfilling selection criteria for the study of age-and sex-specific incidence. Lorraine, a large and well-conducted study, was chosen as reference, and ages 25-34 and 35-44 years at onset were the reference for comparisons when analyses were restricted to ≤ 34 and ≥ 35 years respectively. Results were in general similar for the core analysis, women, men, ages below 35 years at onset and ages > 35 years at onset, with negligible differences. As seen from the core model, 7-fold differences in RRs were seen, with differences in RRs in Catania, 1.39 (1.01-1.91), Reggio Emilia-Modena, 0.33 (0.24-0.45), and the French West Indies, 0.20 (0.16-0.29) proving statistically significant. Incidence among women was triple that of men 2.9 (1.87-2.57). The mean increase in incidence with time was 9% (4%-15%) per year in both sexes. Incidence was different when measured using MRI-based criteria (McDonald criteria included) in the core model, RR 0.68 (0.55-0.85).

Complementary analysis revealed some discrepancies. Models for ages ≥ 35 years revealed the highest incidences in the UK, 1.66 (1.30-2.13), and Catania, 1.43 (1.02-2.61), with an F/M ratio of 1.96 (1.67-2.31), 1/3 lower than those seen for the younger age groups. The analysis of men aged ≥ 35 years at onset showed the highest, 20%

(7%-34%), statistically significant increase in incidence per year, which almost tripled that seen among women of the same age, i.e., 7%. MRI-based diagnostic criteria had the highest impact on populations aged ≤ 35 years, 0.43 (0.35-0.53). When separate models were adjusted for age and sex, the above-mentioned incidence increased with study midpoint, i.e., ages ≥ 35 years in both sexes, by 12% (5%-20%) annually, together with a 5% (3%-6%) increase per degree of latitude, present across all age- and sex- or age-groups. The increase per degree of latitude was significant and rose with age and male sex, ranging from 3% for both sexes aged ≤ 34 years to 6% for men aged ≥ 35 years.

Time series from selected surveys are depicted in Figure 4. Seven reports on Nordic, eight on Italian, and two on Greek and French Caribbean populations covered 5- to 10-year incidence figures for long periods from 1943 to 2007. Three surveys, one French and two Spanish, furnished time-series data for annual counts for the period 1985-2002. In general, MSI increased with: (a) high figures in northern and southern continental populations, reaching four to seven per 100,000 person-years but plotting different shapes, i.e., sharply decreasing in the most recent study period in northern populations (frequently attributed by authors to incomplete case-finding due to diagnostic delay) and yet increasing in Italian populations; and, (b) lower incidences in Greek and French Caribbean populations. Profiles from annual counts were difficult to assess for Alcoi and Lower

Table 3 Selected data from surveys with available age- and sex-specific incidence for periods of clinical onset in EEA populations

Survey population Incidence period Person/years Reference	No. cases	Diagnostic criteria	Incidence			Stratified F/M M-H	F/M ratio	Diagnostic delay Months Mean/median DD	Mid time point Year (1987-2000)	Latitude Degrees N
			Crude	Adjusted						
			Women	Men	Both					
Lorraine 1990-2002 30070439 Debouverie 2007 [31]	1658	Poser D,Pr, (NSO)	7.68	3.26	5.51	2.50 (2.24-2.77)	2.45	-	1996	49
Reggio Emilia & Modena 1985-1990 6061343 Guidetti 1995 [36]			7.76	3.16	5.43					
United Kingdom 1993-2000 11745641 Alonso 2007 [48]	105	Mc Alpine D,Pr (NSO)	2.37	0.99	1.70	2.58 (1.68-3.97)	2.55	-	1987.5	44.28
Catania 1990-1999 3221760 Nicoletti 2005 [32]			2.45	0.95	1.69					
Faroe Islands 1986-2007 1019548 Joensen 2010 [40]	642	Poser D,Pr or MacDonald D,Pr (NSO)	7.42	3.44	5.47	2.26 (1.91-2.67)	2.24	-	1996.5	53.51
Västerbotten 1988-1997 2551521 Sundström 2003 [37]			7.45	3.30	5.36					
Ferrara 1990-2003 4937521 Granieri 2007 [34]	155	Poser CDP,Pr, LSDPr	5.87	3.65	4.81	1.68 (1.21-2.33)	1.77	21 m	1994.5	37.3
			6.02	3.58	4.84					
	43	Poser CD, LSD, or McDonald for one attack (separate criteria for PPMS forms)	5.51	5.21	4.32	1.82 (0.99-3.35)	1.59	-	1996.5	62.01
			5.90	5.23	4.48					
	133	Poser CDP,Pr, LSDPr	6.73	3.69	5.21	1.94 (1.36-2.77)	1.83	-	1992.5	65.02
			7.23	3.72	5.43					
	200	Poser D,Pr (NSO)	5.39	2.25	3.83	2.66 (1.94-3.63)	2.62	15.4 m (in 1990)	1996.5	44.5
			5.77	2.18	3.96			6.1 m (in 2003)		

Table 3 Selected data from surveys with available age- and sex-specific incidence for periods of clinical onset in EEA populations (Continued)

San Marino	33	Poser D,Pr (NSO)	11.69	3.96	7.93	2.95	3.13	18.3 m (in 1990)	1997.5	43.56
1990-2005			10.46	3.80	7.25	(1.32-6.56)		1 m (in 2005)		
415540										
Granieri 2008 [35]										
Catania	108	Poser CDP,Pr,LSDPr	8.43	5.28	6.94	1.69	1.77	17 m	2002	37.3
2000-2004			8.72	5.24	6.96	(1.14-2.49)				
1549580										
Nicoletti 2011 [10]										
French West Indies	130	2005 revised McDonald (NSO)	1.75	0.46	1.14	3.79	4.20	-	2000	15.2
1992-2007			1.71	0.44	1.12	(2.45-5.87)				
11434927										
Cabre 2009 [8]										
Beta for F/M M-H in ordinates linear regression	-	-	-	-	-	-	-	-		
All data sets									0.022	-0.029
									(-0.006, 0.05)	(-0.035, -0.022)
(French West Indies excluded)									-0.026	-0.006
									(-0.047, -0.006)	(-0.014, 0.002)




Figure 3 Age- and sex-specific incidences of selected EEA surveys.

Aragon (Spain) [57,58] due to unstable data, and clearly increasing for Lorraine (France) [31].

The full panorama appears to provide three different geographical and calendar-time related patterns as determined by the increasing rates, ranging from two to seven per million, and lags of approximately 10-20 calendar years. These patterns were as follows: first, northern populations generally exhibited rising incidences in the 1960s, 1970s and 1980s, with a drop in incidence in the most recent study period, and a complex, different profile with low incidence in the Faroes during the period

1960-1970 [19,49,51,55]; second, Italian populations showed heavily increasing rates from 1-2 to 6-7 per 100,000 during the 1970s, occasionally with a delay of one or more decades, such as the increase in Nuoro which was paralleled 15 years later by Catania and Lorraine, a French mainland population which, since 1990, has registered a magnitude and trend similar to that of Catania; and third, populations in Evros, Greece 1974-1999, where the starting point was the lowest among those studied, 0.66 per 100,000, and the French West Indies 1992-2007, which displayed a rise within a narrow range of 1-2.5 per


Table 4 Results from log-linear models (binomial function), OR and 95%CI

Study population, incidence period		Core analysis	Both sexes	Both sexes	Women	Men
		All ages both sexes	Age at onset <35y	Age at onset ≥35y	Age at onset ≥35y	Age at onset ≥35y
First author and reference	Lorraine 1990-2002	1	1	1	1	1
	Debouverie 2007 [31]					
	Reggio Emilia 85-1989	0.33	0.37	0.25	0.28	0.18
	Guidetti 1995 [36]	(0.24-0.45)	(0.29-0.48)	(0.17-0.36)	(0.19-0.42)	(0.09-0.37)
	UK cohort 1993-2000	1.22	0.57	1.66	1.59	1.55
	Alonso 2007 [48]	(0.94-1.59)	(0.48-0.66)	(1.30-2.13)	(1.28-1.96)	(1.03-2.35)
	Catania 1990-1999	0.98	0.90	0.87	0.84	0.90
	Nicoletti 2005 [32]	(0.72-1.32)	(0.72-1.12)	(0.63-1.20)	(0.61-1.17)	0.53-1.50)
	Faroe Islands 86-2007	0.94	0.83	0.91	0.80	1.02
	Joensen 2011 [19]	(0.63-1.39)	(0.55-1.25)	(0.57-1.48)	(0.45-1.45)	(0.49-2.10)
	Västerbotten 88-1997	1.07	1.03	1.00	0.96	1.02
	Sundström 2003 [37]	(0.79-1.46)	(0.81-1.32)	(0.72-1.39)	(0.68-1.36)	(0.61-1.70)
	Ferrara 90-2003	0.74	0.79	0.64	0.74	0.49
	Granieri 2007 [34]	(0.55-0.99)	(0.65-0.97)	(0.48-0.86)	(0.55-0.98)	(0.29-0.81)
	San Marino 90-2005	1.44	1.43	1.19	1.34	0.81
	Granieri 2008 [35]	(0.93-2.23)	(0.92-2.23)	(0.66-2.15)	(0.71-2.54)	(0.25-2.61)
	Catania 2000-2004	1.39	1.19	1.43	1.06	2.07
	Nicoletti 2011 [10]	(1.01-1.91)	(0.90-1.57)	(1.01-2.00)	(0.72-1.57)	(1.26-3.38)
	West Indies 1992-2007	0.21	0.19	0.21	0.26	0.11
	Cabre 2009 [8]	(0.16-0.29)	(0.15-0.25)	(0.15-0.29)	(0.19-0.35)	(0.06-0.22)
Age-groups	0-14y	0.01 (0.008-0.02)	0.01 (0.008-0.02)	-	-	-
	15-24y	0.50 (0.39-0.64)	0.47 (0.42-0.52)	-	-	-
	25-34y	1	1	-	-	-
	35-44y	0.84 (0.67-1.04)	-	1	1	1
	45-54y	0.56 (0.44-0.71)	-	0.66 (0.55-0.78)	0.61 (0.52-0.71)	0.71 (0.52-0.97)
	55-64y	0.19 (0.14-0.25)	-	0.21 (0.17-0.27)	0.17 (0.14-0.22)	0.29 (0.20-0.44)
	≥65y	0.02	-	0.02	0.02	0.03

Table 4 Results from log-linear models (binomial function), OR and 95%CI (Continued)

		(0.01-0.04)		(0.01-0.04)	(0.01-0.04)	(0.01-0.06)
Sex (reference men)		2.19	2.81	1.96	-	-
		(1.87-2.57)	(2.51-3.14)	(1.67-2.31)		
Mid time point incidence period *		1.09	1.06	1.12	1.07	1.20
		(1.04-1.15)	(1.01-1.12)	(1.05-1.20)	(0.99-1.15)	(1.07-1.34)
Latitude degrees*		1.04	1.03	1.05	1.04	1.06
		(1.03-1.05)	(1.02-1.04)	(1.03-1.06)	(1.02-1.05)	(1.03-1.08)
Diagnostic criteria*	Poser	1	1	1	1	1
	Other than Poser's (McAlpine) MRI data not considered	0.73	0.71	0.77	0.59	0.99
		(0.41-1.30)	(0.40-1.26)	(0.35-1.67)	(0.25-1.41)	(0.25-3.87)
	McDonald or Poser and MacDonald including MRI evidence of spread	0.68	0.43	0.94	1.06	0.76
		(0.55-0.85)	(0.35-0.53)	(0.71-1.22)	(0.80-1.41)	(0.49-1.26)

*Models including the variables indicated in results but not the survey place/time variable.



100,000 that started in Evros at the end of century and then appeared, after a 15-year delay, in the French West Indies [8,10,27,32,53].


To sum up, in post-1980 periods rates of close on 6-8 per 100,000 were seen in the majority of EEA populations, preceded by increasing and already stable trends in some Nordic (Hordaland, Oppland, Iceland), Italian (Nuoro, Sassari), and French mainland (Lorraine) populations; meanwhile, low but rising figures of 1-3 per 100,000 were still being seen at the end of the century in Greek and Caribbean populations. Where described, variations in incidence were reflected in all age-groups and both sexes. The time-related change (slope) in Nordic populations before the 1980s appeared to be replicated during the 1980s and 1990s by Italian and French populations, and at a later stage, during the 1990s and beyond, by Greek and Caribbean populations, which solely show rising figures and shorter study periods.

Discussion

The results of this study show that, in recent decades, MSI in EEA populations has been measured using different methods, geographically selected by residence, and has sometimes been reported by age and calendar time at “MS diagnosis”, a health-care variable that is easier to identify than that which it has replaced, i.e., “clinical onset”. Post-1985 results suggest a dynamic picture of MSI, with regular features (peak values for women aged 25-34 years, similar F/M ratios which are higher in the young age strata and youngest populations) and seven-fold variations which are better explained by local changes than by links to latitude (3-fold across 50 degrees latitude, but small if continentally considered) or time (a 2-fold increase per decade). The historical time series suggest increases, initially in the north and more recently in the south, reaching similar levels, 5-7 per 100,000 population, with figures that are still low in Greece and the French Caribbean. These results do not reveal temporal drops in incidence, except for the Faroes, age-specific bimodality

or rising incidences in women linked to an increase in the F/M ratio. When it comes to data analysis and interpretation of results, limitations include: infrequent description of temporal relationships between the diagnostic process and end of case-finding periods; lack of systematic assessment of impact of health service innovations on MS diagnosis (not systematically searched for); and cultural-behavioural differences on seeking diagnosis after mild symptom onset.

Selection might partly account for our results, firstly due to the choice of population by EEA neurologists conducting surveys. Secular trend analysis was mainly based on two very different but relatively homogeneous populations and medical services, i.e., Nordic and Italian. This bipolar pattern was not present in post-1985 data, in which Nordic populations were comparatively underrepresented. Interestingly, the large, sevenfold, variation is evident in both data sets, secular and post-1985, and is therefore unlikely to have been biased in the same direction by selection. Selection might have been determined by exclusion of surveys reporting age and time-point at MS diagnosis. A data plot of some surveys rejected due to incidence being calculated by age-at-diagnosis [26,30,33,46,60] indicates that three incidence features, namely, high magnitude, increase in incidence among persons aged ≥ 35 years and rising time trends, are more clearly revealed when seen from new diagnoses (see Figure 5) than from onsets in Figure 3. This view suggests that the increase in MS diagnoses is higher than the increase in MS onsets. The shortening of MS diagnostic delays in post-1985 surveys, likely restricted to the RRMS form [54], has frequently been described in Italian populations [28,54] but such intervals tend to be more stable in Nordic populations [59]. Diagnostic delay after symptom onset decreased from five years in the mid- or late 1980s in Norway and Italy to two years in the last decade in Spain [26,28,61]. We believe that part of the rise in MS incidence reflects improved access to neurological services at ages considerably later than age at MS onset, with it being impossible, in




cases where mild first relapses are neglected, to capture patients who never reach neurological experts. The different age-specific incidence profile and results from complementary analysis showing the highest risk among women aged ≥ 35 years, suggest that the large UK survey [25] might contain a large proportion of women misclassified by age due to inaccurate reporting of onsets. The use of McDonald's or theoretically more sensitive mixed criteria [62] was associated with low incidence, a paradox probably explained by the fact that such criteria were applied in survey locations and study periods when MSI was low, such as the French West Indies. The high F/M ratio in the young West Indian population and stable trend are consistent with the stable F/M ratios observed for incident patients registered in Sweden over the period 1946-2005 [63].

Time-related changes in post-1985 measurements were few, with the most relevant possibly being the rise in incidence among ≥ 35 -year-olds. Bimodality by age at onset, as described in old surveys on black populations in the USA and recently suggested in Newcastle (Australia) for the period 1986-1996 [64], was not in evidence in our data. The explanation for both our and the Newcastle figures might conceivably lie in the capture of silent, mild MS cases by age-differential ascertainment, underlying age-differential access to neurological diagnosis bimodality in old surveys [22,65-67]. The low, extensively studied, incidences in the Faroe Islands, the modest decreasing trend in Hordaland for the 1980-1995 midpoint interval, and the occasional decline registered in Denmark [20] remain unexplained.

While substantial, several-fold variation in MSI was linked to place and only twofold variation was linked to latitude or time, such variation was not linked to more sensitive, MRI-based diagnostic criteria [33,40].

MS registration in Nordic populations, and more recently in Ferrara or Catania, shows that the magnitude of local change matches recorded international differences across longer periods and affects all age and sex groups. Improvement in diagnostic ascertainment across all ages in recent decades is evident from improved access to neurological expertise, laboratory testing and MRI, and is frequently reported in Nordic and Italian studies. The fact that earlier low incidence persists being low after prolonged survey updates in Ferrara, Catania and Hordaland, may suggest that diagnostic improvement basically affects clinically recent and mildest MS forms. Such ubiquitous factor might explain secular and post-1985 time trends in the EEA. This interpretation is difficult to reconcile with two views held by local researchers claiming a true increase in MSI: first, that suggested by Italian and mainland-based French neuroscientists, whereby the increase is said to be attributable to the biological impact of changes in women's life-style [10,23,31,44]; second, that relatively restricted to returning continental immigration, reported in the French West Indies as a lagged phenomenon imported from a higher-risk environment [8,68]. Major reasons for rejecting such interpretations or modulating them in favour of better detection in mild cases are: (1) that the increase in MSI among women or older women is, if anything, restricted to single surveys (not seen here), and that changes in EU women's lifestyles (e.g., occupational) were generalised and predated studies on Scandinavian populations not showing such an increase, (<http://www.ilo.org>); (2) that rising MSI in the French West Indies pertains to particularly severe forms [8,69], thus potentially representing the tip of the iceberg already uncovered in the majority of other surveyed EEA populations, and (3) rising MSI is seen



in men. Disregarding potential effects of D Vitamin dietary or childhood hygienic changes, race and latitude, we would prefer to propose that increased population concern about MS symptoms, referral and access to neurological expertise and, recently, to technology acting on stable MSIs might account for the entire EEA pattern, particularly due to the increasing proportion of women active in non-domestic occupational work among those of working age in EEA-surveyed populations. The geographically and time-related decreasing differences in MSI in the EEA by asymptotic trend towards an incidence of 5-7 per 100,000, may suggest that MS appears to behave invariantly with respect to time and space at a stage characterised by improvements in diagnosis and treatment, and by the loss of the natural history due to the widespread use of immune-modulatory treatments that are partly effective and not free of side-effects [70,71]. MS diagnostic functions at EEA might mirror the parallel logarithmic or sigmoid functions outlined in Figure 6. Such pattern defines a framework that is inevitably present in different approaches (surveys, registries, monitoring systems), potentially providing what are apparently diverging but are, in reality, consistent results on different patients. On combining worldwide data from 38 incidence periods reported in 1966-2007, i.e. the global longitudinal approach, Alonso and Hernan [25] describe increasing time-trends for incidence and F/M ratios attenuated after 1980, findings that are consistent with ours. Register-based, calendar-time-limited incident approaches (see the post-1985 window in Figure 6) and prevalence approaches [72] accumulate an increasing

proportion of frequently treated cases detected in high-incidence settings.

Given the suggested difficulties found in measuring MSI, it would appear that the proposal of a pilot surveillance system active under suspect alarm conditions, similar for instance to those designed and tested for Guillain-Barré syndrome [73], may not be opportune for a number of reasons (lack of reported outbreaks or an expected preventive response, problems managing suspected cases), at least until MSI levels exceed those described for Nordic populations or new aetiological agents are identified. Instead, some of the existing monitoring alternatives appear to be reasonable, subject to being population- rather than hospital-based. Fortunately, there is long experience of monitoring EEA populations.

Conclusions

We conclude that the reported rising incidence of MS in the EEA might be attributable to improved ascertainment and that population-based MS monitoring by selected centres may be useful.

Competing interest

The authors declare that there are no conflicts of interest. Enrique Alcalde-Cabero's work was partly funded by the above-mentioned grant from Biogen Idec.

Authors' contributions

E Alcalde-Cabero contributed to the design of the methods and protocols, refined and managed the study database, and conducted preliminary tabulations and statistical analyses; J Almazán-Isla supervised data collection and data entry; J. de Pedro-Cuesta conceived the study, coordinated the research team, and collaborated with E Alcalde on the draft of the first manuscript. All authors contributed by commenting on the manuscript.

Acknowledgements

This study was made possible by the fact that a number of authors of reported studies provided supplementary data on the reported numerators and population figures, and revised the results submitted. Accordingly, the authors of this study are most grateful to: Alstadhaug K.B., Norway; Granieri E. and Nicoletti A., Italy; Debouverie M. and Cabre P., France; Sundström P., Sweden; and Joensen P., Faroe Islands, Denmark. Thanks must likewise go to Javier Damian and Leszek Stawiarz for invaluable comments, to Marta Valente at Biogen Idec, Lisbon, for support received, and Michael Benedict for his help with the review and revision of the English-language version of the manuscript.

Author details

¹National Centre for Epidemiology, Carlos III Institute of Health, and Consortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Av Monforte de Lemos 5, Madrid 28029, Spain. ²Neurology Department, Puerta de Hierro Clinic, Madrid Autonomous University, Majadahonda, Spain. ³Neurology Department, Santa Maria Hospital, Av. Prof. Egas Moniz, Lisbon 1600-001, Portugal.

Received: 16 January 2013 Accepted: 4 June 2013

Published: 12 June 2013

References

1. Fogdell A, Olerup O, Fredrikson S, Vrethem M, Hillert J: **Linkage analysis of HLA class II genes in Swedish multiplex families with multiple sclerosis.** *Neurology* 1997, **48**:758–762.
2. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, et al: **Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.** *Nature* 2011, **476**:214–219.
3. Baranzini SE, Nickles D: **Genetics of multiple sclerosis: swimming in an ocean of data.** *Curr Opin Neurol* 2012, **25**:239–245.
4. Jin Y, de Pedro-Cuesta J, Soderstrom M, Stawiarz L, Link H: **Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis.** *J Neurol Sci* 2000, **181**:56–64.
5. Jin YP, de Pedro-Cuesta J, Lopez-Abente G, Link H: **Birth cohort effects in multiple sclerosis.** *Ann Epidemiol* 2003, **13**:252–260.
6. Hawkes CH, Macgregor AJ: **Twin studies and the heritability of MS: a conclusion.** *Mult Scler* 2009, **15**:661–667.
7. Gale CR, Martyn CN: **Migrant studies in multiple sclerosis.** *Prog Neurobiol* 1995, **47**:425–448.
8. Cabre P: **Environmental changes and epidemiology of multiple sclerosis in the French West Indies.** *J Neurol Sci* 2009, **286**:58–61.
9. Benito-Leon J: **Are the prevalence and incidence of multiple sclerosis changing?** *Neuroepidemiology* 2011, **36**:148–149.
10. Nicoletti A, Patti F, Lo Fermo S, Messina S, Bruno E, Quattrocchi G, Laisa P, Cilia S, Mostile G, Marziolo R, et al: **Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey.** *Mult Scler* 2011, **17**:273–280.
11. Hernan MA, Jick SS, Olek MJ, Jick H: **Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study.** *Neurology* 2004, **63**:838–842.
12. Flachenecker P, Stuke K: **National MS registries.** *J Neurol* 2008, **255** (Suppl 6):102–108.
13. Ahlgren C, Oden A, Toren K, Andersen O: **Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations.** *Acta Neurol Scand* 2009, **119**:313–320.
14. Otero S, Batlle J, Bonaventura I, Brieua L, Bufill E, Cano A, Carmona O, Escartin A, Marco M, Moral E, et al: **Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia.** *Rev Neurol* 2010, **50**:623–633.
15. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F: **Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden.** *BMJ* 2011, **343**:d5956.
16. de Sa J, Alcalde-Cabero E, Almazan-Isla J, Sempere A, de Pedro-Cuesta J: **Capture-recapture as a potentially useful procedure for assessing prevalence of multiple sclerosis: methodologic exercise using portuguese data.** *Neuroepidemiology* 2012, **38**:209–216.
17. Esbjerg S, Keiding N, Koch-Henriksen N: **Reporting delay and corrected incidence of multiple sclerosis.** *Stat Med* 1999, **18**:1691–1706.
18. Thygesen LC, Keiding N, Koch-Henriksen N: **Evaluating a parametric model to correct multiple sclerosis incidence for reporting delay.** *Stat Med* 2011, **30**:896–898.
19. Joensen P: **Multiple sclerosis: variation of incidence of onset over time in the Faroe Islands.** *Mult Scler* 2011, **17**:241–244.
20. Koch-Henriksen N, Bronnum-Hansen H, Hyllested K: **Incidence of multiple sclerosis in Denmark 1948-1982: a descriptive nationwide study.** *Neuroepidemiology* 1992, **11**:1–10.
21. Kurtzke JF, Heltberg A: **Multiple sclerosis in the Faroe Islands: an epitome.** *J Clin Epidemiol* 2001, **54**:1–22.
22. Poskanzer DC, Schapira K, Miller H: **Epidemiology of multiple sclerosis in the counties of Northumberland and Durham.** *J Neurol Neurosurg Psychiatr* 1963, **26**:368–376.
23. Debouverie M: **Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France.** *J Neurol Sci* 2009, **286**:14–17.
24. Krokki O, Bloigu R, Reunanen M, Remes AM: **Increasing incidence of multiple sclerosis in women in Northern Finland.** *Mult Scler* 2011, **17**:133–138.
25. Alonso A, Hernan MA: **Temporal trends in the incidence of multiple sclerosis: a systematic review.** *Neurology* 2008, **71**:129–135.
26. Celius EG, Vandvik B: **Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period.** *Eur J Neurol* 2001, **8**:463–469.
27. Granieri E, Casetta I, Govoni V, Tola MR, Marchi D, Murgia SB, Ticca A, Pugliatti M, Murgia B, Rosati G: **The increasing incidence and prevalence of MS in a Sardinian province.** *Neurology* 2000, **55**:842–848.
28. Ranzato F, Perini P, Tzintzeva E, Tiberio M, Calabrese M, Ermani M, Davetog F, De Zanche L, Garbin E, Verdelli F, et al: **Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey.** *Mult Scler* 2003, **9**:387–392.
29. Pai M, McCulloch M, Gorman JD, Pai N, Enanoria W, Kennedy G, Tharyan P, Colford JM Jr: **Systematic reviews and meta-analyses: an illustrated, step-by-step guide.** *Natl Med J India* 2004, **17**:86–95.
30. Alstadhaug KB, Olavsen J, Salvesen R: **[Occurrence of multiple sclerosis in Nordland, 1970-1999].** *Tidsskr Nor Laegeforen* 2005, **125**:431–433.
31. Debouverie M, Pittion-Vouyovitch S, Louis S, Roederer T, Guillemin F: **Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France.** *Mult Scler* 2007, **13**:962–967.
32. Nicoletti A, Patti F, Lo Fermo S, Sorbello V, Reggio E, Maimone D, Zappia M, Reggio A: **Possible increasing risk of multiple sclerosis in Catania, Sicily.** *Neurology* 2005, **65**:1259–1263.
33. Cocco E, Sardu C, Massa R, Mamusa E, Musu L, Ferrigno P, Melis M, Montomoli C, Ferretti V, Coghe G, et al: **Epidemiology of multiple sclerosis in south-western Sardinia.** *Mult Scler* 2011, **17**:1282–1289.
34. Granieri E, Economou NT, De Gennaro R, Tola MR, Caniatti L, Govoni V, Fainardi E, Casetta I: **Multiple sclerosis in the province of Ferrara: evidence for an increasing trend.** *J Neurol* 2007, **254**:1642–1648.
35. Granieri E, Monaldini C, De Gennaro R, Guttmann S, Volpini M, Stumpo M, Fazio P, Casetta I: **Multiple sclerosis in the Republic of San Marino: a prevalence and incidence study.** *Mult Scler* 2008, **14**:325–329.
36. Guidetti D, Cavalletti S, Merelli E, Zanon P, Simonazzi P, Sola P, Solime F: **Epidemiological survey of multiple sclerosis in the provinces of Reggio Emilia and Modena, Italy.** *Neuroepidemiology* 1995, **14**:7–13.
37. Sundstrom P, Nystrom L, Forsgren L: **Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Vasterbotten County in northern Sweden.** *J Neurol Neurosurg Psychiatr* 2003, **74**:29–32.
38. Hirst C, Ingram G, Pickersgill T, Swingle R, Compston DA, Robertson NP: **Increasing prevalence and incidence of multiple sclerosis in South East Wales.** *J Neurol Neurosurg Psychiatr* 2009, **80**:386–391.
39. Grimaldi LM, Salemi G, Grimaldi G, Rizzo A, Marziolo R, Lo Presti C, Maimone D, Savettieri G: **High incidence and increasing prevalence of MS in Enna (Sicily), southern Italy.** *Neurology* 2001, **57**:1891–1893.
40. Joensen P: **Multiple sclerosis incidence in the Faroe Islands 1986-2007.** *Acta Neurol Scand* 2010, **121**:348–353.
41. Ragonese P, Salemi G, D'Amelio M, Gammino M, Aridon P, Savettieri G: **Multiple sclerosis in southern Europe: Monreale City, Italy. A twenty-year follow-up incidence and prevalence study.** *Neuroepidemiology* 2004, **23**:306–309.

42. Salemi G, Ragonese P, Aridon P, Scola G, Saporito V, Conte S, Savettieri G: **Incidence of multiple sclerosis in Bagheria City, Sicily, Italy.** *Neurol Sci* 2000, **21**:361–365.
43. Granieri E, Malagu S, Casetta I, Tola MR, Govoni V, Paolino E, Monetti VC: **Multiple sclerosis in Catania. A reappraisal of incidence and prevalence in Ferrara.** *Arch Neurol* 1996, **53**:793–798.
44. Nicoletti A, Lo Bartolo ML, Lo FS, Cocuzza V, Panetta MR, Marletta C, Ciancio MR, Cataldi ML, Patti F, Reggio A: **Prevalence and incidence of multiple sclerosis in Catania, Sicily.** *Neurology* 2001, **56**:62–66.
45. Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Pirastru MI, Murgia B, Mannu L, Sanna G, Rosati G: **Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk.** *Acta Neurol Scand* 2001, **103**:20–26.
46. Eliasdottir OJ, Olafsson E, Kjartansson O: **Incidence of multiple sclerosis in Iceland, 2002-2007: a population-based study.** *Mult Scler* 2011, **17**:909–913.
47. Cavalletti S, Merelli E, Cavazzuti M, Guidetti D: **Frequency of MS in the province of Modena, 1970-1990.** *Acta Neurol Scand* 1994, **90**:377–381.
48. Alonso A, Jick SS, Olek MJ, Hernan MA: **Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.** *J Neurol* 2007, **254**:1736–1741.
49. Benediktz J, Stefansson M, Guomundsson J, Jonasdottir A, Fossdal R, Gulcher J, Stefansson K: **The natural history of untreated multiple sclerosis in Iceland. A total population-based 50 year prospective study.** *Clin Neurol Neurosurg* 2002, **104**:208–210.
50. Gronlie SA, Myrvoll E, Hansen G, Gronning M, Mellgren SI: **Multiple sclerosis in North Norway, and first appearance in an indigenous population.** *J Neurol* 2000, **247**:129–133.
51. Grytten N, Glad SB, Aarseth JH, Nyland H, Midgard R, Myhr KM: **A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway.** *Neurology* 2006, **66**:182–186.
52. Midgard R, Riise T, Svanes C, Kvale G, Nyland H: **Incidence of multiple sclerosis in More and Romsdal, Norway from 1950 to 1991. An age-period-cohort analysis.** *Brain* 1996, **119**(Pt 1):203–211.
53. Piperidou HN, Heliopoulos IN, Maltezos ES, Milonas IA: **Epidemiological data of multiple sclerosis in the province of Evros, Greece.** *Eur Neurol* 2003, **49**:8–12.
54. Pugliatti M, Riise T, Sotgiu MA, Sotgiu S, Satta WM, Mannu L, Sanna G, Rosati G: **Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia.** *Neuroepidemiology* 2005, **25**:129–134.
55. Risberg G, Aarseth JH, Nyland H, Lauer K, Myhr KM, Midgard R: **Prevalence and incidence of multiple sclerosis in Oppland County: a cross-sectional population-based study in a landlocked county of Eastern Norway.** *Acta Neurol Scand* 2011, **124**:250–257.
56. Rosati G, Aiello I, Pirastru MI, Mannu L, Sanna G, Sau GF, Sotgiu S: **Epidemiology of multiple sclerosis in Northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians.** *Neuroepidemiology* 1996, **15**:10–19.
57. Mallada-Frechin J, Matias-Guiu GJ, Martin R, Lopez-Arlandis JM, Camacho-Cuartero JM, Beltran I, Molto JM, Falip R, Abellan-Miralles I: **Multiple sclerosis incidence in the Alcoi Health district. 12-year-long study (1986-1997).** *Rev Neurol* 2000, **30**:1128–1131.
58. Modrego PJ, Pina MA: **Trends in prevalence and incidence of multiple sclerosis in Bajo Aragon, Spain.** *J Neurol Sci* 2003, **216**:89–93.
59. Sumelahti ML, Tienari PJ, Hakama M, Wikstrom J: **Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses.** *J Neurol Neurosurg Psychiatr* 2003, **74**:25–28.
60. Papatathanasopoulos P, Gourzoulidou E, Messinis L, Georgiou V, Leotsinidis M: **Prevalence and incidence of multiple sclerosis in western Greece: a 23-year survey.** *Neuroepidemiology* 2008, **30**:167–173.
61. Fernandez O, Fernandez V, Arbizu T, Izquierdo G, Bosca I, Arroyo R, Garcia Merino JA, de RE: **Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).** *J Neurol* 2010, **257**:1500–1507.
62. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, et al: **Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.** *Ann Neurol* 2011, **69**:292–302.
63. Bostrom I, Stawiarz L, Landtblom AM: **Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg).** *Mult Scler* 2013, **19**:46–52.
64. Barnett MH, Williams DB, Day S, Macaskill P, McLeod JG: **Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study.** *J Neurol Sci* 2003, **213**:1–6.
65. Alter M: **Multiple sclerosis in the Negro.** *Arch Neurol* 1962, **7**:83–91.
66. Fischman HR: **Multiple sclerosis: a two-stage process?** *Am J Epidemiol* 1981, **114**:244–252.
67. Fischman HR: **Multiple sclerosis: a new perspective on epidemiologic patterns.** *Neurology* 1982, **32**:864–870.
68. Cabre P: **Migration and multiple sclerosis: the French West Indies experience.** *J Neurol Sci* 2007, **262**:117–121.
69. Jeannin S, Deschamps R, Chausson N, Cabre P: **Response to interferon-Beta treatment in afro-caribbeans with multiple sclerosis.** *Mult Scler Int* 2011, **2011**:950126.
70. Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, et al: **Three years of experience: the Italian registry and safety data update.** *Neurol Sci* 2011, **31**(Suppl 3):295–297.
71. Piehl F, Holmen C, Hillert J, Olsson T: **Swedish natalizumab (Tysabri) multiple sclerosis surveillance study.** *Neurol Sci* 2011, **31**(Suppl 3):289–293.
72. Ahlgren C, Oden A, Lycke J: **High nationwide prevalence of multiple sclerosis in Sweden.** *Mult Scler* 2011, **17**:901–908.
73. Cuadrado JI, de Pedro-Cuesta J, Ara JR, Cemillan CA, Diaz M, Duarte J, Fernandez MD, Fernandez O, Garcia-Lopez F, Garcia-Merino A, et al: **Public health surveillance and incidence of adulthood Guillain-Barre syndrome in Spain, 1998-1999: the view from a sentinel network of neurologists.** *Neurol Sci* 2004, **25**:57–65.

doi:10.1186/1471-2377-13-58

Cite this article as: Alcalde-Cabero et al.: Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring. *BMC Neurology* 2013 **13**:58.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

